Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function

NCT01240967 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01240967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01240967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
July 31, 2011
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, patients, pharmacokinetics, renal impairment